Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study | Synapse
August 2, 2021Open Access
Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study
Key Points
Key points are not available for this paper at this time.
Abstract
Vosoritide treatment has safe and persistent growth-promoting effects in children with achondroplasia treated daily for two years.